Efficacy， safety and cost-effectiveness evaluation of voriconazole original and generic drugs

TANG Ganling; XIE Xiangwei; LUO Xiandan; LU Yanli; JIANG Huixian; LI Jingyi; HUANG Xiaoman; ZHANG Hongliang

doi:10.6039/j.issn.1001-0408.2024.07.11

您当前的位置：

首页 >

文章列表页 >

Efficacy， safety and cost-effectiveness evaluation of voriconazole original and generic drugs

更新时间：2025-09-25

- Efficacy， safety and cost-effectiveness evaluation of voriconazole original and generic drugs
- ZHONGGUO YAOFANG Vol. 35, Issue 7, Pages: 831-836(2024)
- 作者机构：
  
  广西医科大学第一附属医院药学部，南宁　530021
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.07.11
  CLC： R978.5
- Received：23 November 2023，
  
  Revised：2024-02-23，
  
  Accepted：23 February 2024，
  
  Published：15 April 2024
- 稿件说明：
移动端阅览
唐甘翎,谢祥威,罗鲜丹,等.伏立康唑原研药与仿制药的有效性、安全性及经济性评价[J].中国药房,2024,35(07):831-836.

TANG Ganling,XIE Xiangwei,LUO Xiandan,et al.Efficacy， safety and cost-effectiveness evaluation of voriconazole original and generic drugs[J].ZHONGGUO YAOFANG,2024,35(07):831-836.
唐甘翎,谢祥威,罗鲜丹,等.伏立康唑原研药与仿制药的有效性、安全性及经济性评价[J].中国药房,2024,35(07):831-836. DOI： 10.6039/j.issn.1001-0408.2024.07.11.

TANG Ganling,XIE Xiangwei,LUO Xiandan,et al.Efficacy， safety and cost-effectiveness evaluation of voriconazole original and generic drugs[J].ZHONGGUO YAOFANG,2024,35(07):831-836. DOI： 10.6039/j.issn.1001-0408.2024.07.11.

摘要

目的

评价伏立康唑仿制药与原研药的有效性、安全性和经济性。

方法

收集本院使用集采中选伏立康唑仿制药（仿制药组）或非中选原研药（原研药组）治疗真菌感染的患者信息。采用倾向性得分匹配消除偏倚。通过临床疗效、影像学表现和微生物试验评估综合疗效，根据感染真菌菌种、基础疾病等对不同人群进行分层并评估不同分层的疗效；使用药物不良反应发生情况评价安全性；采用总费用和药品的用药频度、日均费用等评估经济性。

结果

有436例患者被纳入，经匹配后，两组各有190例。在有效性方面，伏立康唑仿制药和原研药的有效率分别为62.63%和59.47%（

＝0.528）。在安全性方面，伏立康唑仿制药和原研药的不良反应发生率分别为13.68%和7.89%（

＝0.069）。在经济性方面，伏立康唑仿制药平均总费用4 636.26元，原研药平均总费用 8 613.20元（

＜0.001）；仿制药在集采实施后药品替换率上升至87.30%，日均费用下降59.08%。

结论

伏立康唑仿制药在治疗真菌感染的有效性和安全性与原研药相似，且在治疗成本方面经济性更佳。

Abstract

OBJECTIVE

To evaluate the efficacy， safety and cost-effectiveness of generic drugs and original drugs of voriconazole.

METHODS

The information of patients who used voriconazole generic drugs selected in National Centralized Drug Procurement （generic drug group） or non-selected original drugs （original drug group） in the treatment of fungal infection was collected from the our hospital. The propensity score matching was carried out to eliminate bias. The comprehensive efficacy was evaluated according to clinical efficacy， image findings and microbiological test， and stratified analysis of different populations was conducted based on fungal species， underlying diseases， etc.， the efficacy of different stratifications was evaluated. Evaluation of safety was performed by using the incidence of adverse reactions. The total cost， defined daily doses （DDDs） and defined daily dose cost （DDDc） were used to evaluate the cost-effectiveness.

RESULTS

A total of 436 patients were included， and there were 190 patients in each group after matching. In terms of efficacy， the effective rates of voriconazole generic drugs and original drugs were 62.63% and 59.47% （

＝0.528）； in terms of safety， the incidence of adverse reactions caused by generic drugs and original drugs of voriconazole was 13.68% and 7.89%， respectively（

＝0.069）. In terms of cost-effectiveness， the average total cost of generic drugs was 4 636.26 yuan， and that of original drugs wa

s 8 613.20 yuan （

＜0.001）. After the implementation of National Centralized Drug Procurement， replacement rate of generic drugs increased to 87.30%， and DDDc decreased by 59.08%.

CONCLUSIONS

The efficacy and safety of voriconazole generic drugs are similar to those of original drugs in the treatment of fungal infection， and it is more cost-effective in terms of treatment cost.

关键词

Keywords

references

谢金平，张雪瑞，张赫，等 . 国家药品集中采购政策的主要利益相关者分析 [J ] . 中国药房， 2021 ， 32 （ 21 ）： 2677 - 2682 .

XIE J P ， ZHANG X R ， ZHANG H ， et al . Analysis of key stakeholders in the national drug centralized procurement policy [J ] . China Pharm ， 2021 ， 32 （ 21 ）： 2677 - 2682 .

黄仲义，李光慧 . 仿制药质量一致性评价及有关建议 [J ] . 上海医药， 2019 ， 40 （ 7 ）： 3 - 5 .

HUANG Z Y ， LI G H . Suggestions on quality consistency evaluation for generic drugs [J ] . Shanghai Med Pharm J ， 2019 ， 40 （ 7 ）： 3 - 5 .

明丹丹，李军，许璇，等 . 真实世界研究的方法及其在临床研究中的应用 [J ] . 中国药房， 2018 ， 29 （ 15 ）： 2138 - 2143 .

MING D D ， LI J ， XU X ， et al . Methods of real-world research and its application in clinical research [J ] . China Pharm ， 2018 ， 29 （ 15 ）： 2138 - 2143 .

ALASTRUEY-IZQUIERDO A ， CADRANEL J ， FLICK H ， et al . Treatment of chronic pulmonary aspergillosis：current standards and future perspectives [J ] . Respiration ， 2018 ， 96 （ 2 ）： 159 - 170 .

NEOFYTOS D ， STEINBACH W J ， HANSON K ， et al . American Society for Transplantation and Cellular Therapy series，#6：management of invasive candidiasis in hematopoietic cell transplantation recipients [J ] . Transplant Cell Ther ， 2023 ， 29 （ 4 ）： 222 - 227 .

《抗菌药物临床试验技术指导原则》写作组 . 抗菌药物临床试验技术指导原则 [J ] . 中国临床药理学杂志， 2014 ， 30 （ 9 ）： 844 - 856 .

Writing group of Guidance for Clinical Trials of Antibacterial Drugs . Guidance for clinical trials of anti-bacterial drugs [J ] . Chin J Clin Pharmacol ， 2014 ， 30 （ 9 ）： 844 - 856 .

贾继东，程留芳，许建明，等 . 常用肝脏生物化学试验的临床意义及评价共识 [J ] . 中华保健医学杂志， 2010 ， 12 （ 3 ）： 161 - 168 .

JIA J D ， CHENG L F ， XU J M ， et al . Clinical significance and evaluation consensus of common liver biochemical tests [J ] . Chin J Health Care Med ， 2010 ， 12 （ 3 ）： 161 - 168 .

中华预防医学会肾脏病预防与控制专业委员会 . 中国慢性肾脏病早期评价与管理指南 [J ] . 中华内科杂志， 2023 ， 62 （ 8 ）： 902 - 930 .

Kidney Disease Prevention and Control Professional Committee of the Chinese Association of Preventive Medicine . Guidelines for the early evaluation and management of chronic kidney disease in China [J ] . Chin J Intern Med ， 2023 ， 62 （ 8 ）： 902 - 930 .

宋静楠，李佳，何秋毅，等 . 伏立康唑片剂原研药与仿制药治疗侵袭性真菌感染的有效性与安全性比较 [J ] . 今日药学， 2022 ， 32 （ 10 ）： 757 - 761 .

SONG J N ， LI J ， HE Q Y ， et al . Comparison of clinical effectiveness and safety between branded and generic voriconazole tablets in the treatment of invasive fungal infections [J ] . Pharm Today ， 2022 ， 32 （ 10 ）： 757 - 761 .

苏莹，金鹏飞，西娜 . 国产与进口伏立康唑用于肾移植术后肺部真菌感染患者的疗效及安全性比较 [J ] . 中国医院用药评价与分析， 2020 ， 20 （ 10 ）： 1161 - 1163，1167 .

SU Y ， JIN P F ， XI N . Comparison of efficacy and safety between domestic and imported voriconazole in the treatment of pulmonary fungal infection after renal transplantation [J ] . Eval Anal Drug Use Hosp China ， 2020 ， 20 （ 10 ）： 1161 - 1163，1167 .

KOHNO S ， IZUMIKAWA K ， TAKAZONO T ， et al . Efficacy and safety of isavuconazole against deep-seated mycoses：a phase 3，randomized，open-label study in Japan [J ] . J Infect Chemother ， 2023 ， 29 （ 2 ）： 163 - 170 .

张春燕，钟蕾，黄琳，等 . 北京地区近10年伏立康唑致严重不良反应分析 [J ] . 中国新药杂志， 2022 ， 31 （ 16 ）： 1645 - 1649 .

ZHANG C Y ， ZHONG L ， HUANG L ， et al . Analysis of voriconazole-induced serious adverse drug reactions between 2011-2021 in Beijing [J ] . Chin J N Drugs ， 2022 ， 31 （ 16 ）： 1645 - 1649 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy， safety and cost-effectiveness of polyisobutylene-type Gutong plaster in the treatment of osteoarthritis in Chinese adults

Active monitoring and risk factor analysis of tenofovir disoproxil fumarate-induced kidney injury

Cost-utility Analysis of 3 Antiemetic Regimens to Prevent Nausea and Vomiting Caused by Multi-day Cisplatin- containing Chemotherapy Based on the Real World

Related Author

XU Wei

HUANG Xiaoqing

ZHONG Gangpeng

LIU Haijiao

LIU Chaoyi

JING Tianyu

LI Caidong

GU Dianjie

Related Institution

School of International Pharmaceutical Business， China Pharmaceutical University

Dept. of Pharmacy， the Second People’s Hospital of Lanzhou

Liver Disease Research Institute， the Second People’s Hospital of Lanzhou

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰